Why Could COVID-19 Vaccines Cause Adverse Effects Such as Myocarditis?

Posted by A.M. September 18, 2021

Why Could COVID-19 Vaccines Cause Adverse Effects Such as Myocarditis?

Answer: Myocarditis (inflammation of the heart muscle) and Pericarditis (inflammation of the outer lining of the heart) result from the body immune system's response to an infection or a trigger (including the COVID-19 imitating or inactive virus).

Source (CDC)

Australia Department of Health explains (in the section How Do COVID-19 Vaccines Work) that COVID-19 vaccines like BioNTech, Pfizer Comirnaty, Moderna mRNA-1273 Spikevax, and Oxford/AstraZeneca COVID-19 vaccine (AZD1222) Vaxzevria or Covishield trains our body's immune system to recognise and cleanse our bodies from viruses or bacteria that could cause COVID-19.

As the COVID-19 imitating (or inactive) vaccine enters the human body, our immune system learns to spot and deal with the more serious and actual COVID-19 virus.

It is interesting to know that old-school vaccines like Synovac contain the real inactive COVID-19 virus. (A bit scary though, since you can develop a full-on COVID-19 sickness).

As the body learns to cope, the immune system is strengthened while your body specifically learns how to overcome the virus.

Thus, when you do actually contract COVID-19, you give your body a better fighting chance and a higher, faster rate of recovery from COVID-19. This is because your body is no longer caught unaware and your immune system is no longer a novice or ignorant of the disease.

Some are against receiving the vaccine thinking that natural immunity gives them a lesser risk of complications and death from the virus.

Indeed, like with other vaccines, these SARS Cov2 vaccines carry risks of adverse effects and complications such as Myocarditis since your body is receiving an imitation or inactive form of the deadly COVID-19 virus.

SARS-CoV-2 stands for Severe Acute Respiratory Syndrome Coronavirus 2.

However, statistics prove that receiving the CORONAVIRUS-19 vaccine greatly decreases your chance of being hospitalised for serious illness and even death. Check out some reading resources from legitimate sources (listed below).

In saying that, we cannot downplay the risks. No matter how small the percentage of people who die or develop complications from the vaccine (due to underlying medical conditions and allergic reactions), that is still a sad and unfortunate outcome.

Hence, having the vaccine is a personal choice because real, dangerous risks exist both ways, whether you have the vaccine or whether you choose to contract COVID-19 without previous vaccination.

Others say that more people die from the vaccine than the virus itself and that authorities are just hiding the facts. But in this day, it is doubtful that countries can suppress information like that.

And it is unlikely that health authorities are hiding crucial health and safety information from the public on a GLOBAL scale. For what reason, just to make money?

Then again, some say that COVID-19 is just like any other flu and probably has been going on for years. But is it like any other flu really, if you take a look at the severity of the effects of the disease.

One patient (David Mellado) was released after 399 days in the hospital, due to the complications of COVID. He was in a state of coma for weeks. Does that sound like ordinary flu to you?

Other resources of interest:

Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

FDA panel endorses Pfizer’s COVID-19 vaccine booster for people 65 and older, high-risk patients

Key notes:

The U.S. FDA (Food and Drug Administration) advisory panel endorses Pfizer-BioNTech COVID-19 vaccine boosters for people 65-up and people with high risk of occupational exposure and severe COVID-19. The recommendation is to take the booster shot 6 months after the second dose.
The same advisory panel earlier rejected Pfizer Comirnaty booster vaccines for 16 and up.
The panel deliberated that the boosters may benefit the older and vulnerable populations and recognised insufficient data for younger populations. The increased risk of heart inflammation among them and specifically males ages 16 and 17 was considered.
The advisory panel comprised of members of the FDA's Vaccines and Related Biological Products Advisory Committee, (VRBPAC), officials from the CDC (Centers for Disease Control and Prevention, lsrael’s Health Ministry, Pfizer representatives, and other vaccine experts.

Dr. William Gruber is Pfizer's senior vice president of vaccine clinical research and development. He cites Phase 3 trial data that indicates waning protection over time. There is 96% vaccine efficacy within two months after the second dose.

But this drops to 84% by six months. It should be noted that though protection drops against infections, considering trial data results, the vaccine remains effective in preventing hospitalizations.

Dr. Gruber further cites that these reductions are due to waning immunity over time and not due to the delta variant escaping vaccine protection. More data suggests boosters will increase the rate of protection compared with having just 2 doses.

However, the risk of myocarditis presents. Hence, the endorsement is for people ages 65 and up only at this time.

COVID-19 by the Numbers